Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Diamond-Tipped catheter takes on heart rhythm disorder

NCT ID NCT06028919

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested a new ablation catheter (DiamondTemp) against the current standard (Tacticath/Tactiflex) for treating ventricular tachycardia (VT), a life-threatening fast heart rhythm. 61 adults with VT who needed ablation took part. The goal was to see if the new catheter is as safe and effective at reducing VT episodes over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DiamondTemp ablation catheter (device) vs Tacticath/Tactiflex ablation catheter (device)
What this could lead to
If the DiamondTemp catheter works as well as the standard one, it could offer doctors another safe and effective tool to treat VT and reduce the need for painful shocks from defibrillators.
What could go wrong
This is a small, completed trial with only 61 people, so results may not apply to everyone. The new catheter might not be as effective or safe as the current standard, and any ablation procedure carries risks like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Sep 2022

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age to give informed consent specific to national legal requirements. * Subject with 1 of the following: 1. Symptomatic VT (despite optimal medical therapy), 3 or more episodes of VT within 24 h (VT storm). 2. At least 3 episodes of VT requiring anti-tachycardia pacing (ATP) 3. At least one appropriate ICD shock. * Referred for VT ablation by Consultant Electrophysiologist * Subject discussed at cardiac EP MDT * Suitable candidate for intra-cardiac mapping and ablation of arrhythmia. * Subject agrees to comply with study procedures and be available for routine follow up visits for at least 12 months after enrolment. * Subject is willing and able to provide written consent Exclusion Criteria: * BMI \>40kg/m2 * Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations. * Coagulopathy, bleeding diathesis or suspected pro-coagulant state. * Sepsis, active systemic infection or fever (\>100.5 F/38 C) within a week prior to the ablation procedure. * Significant restrictive or obstructive pulmonary disease or chronic respiratory condition. * Renal failure requiring dialysis or renal compromise that in the investigators judgement would increase risk to the subject or deem the subject inappropriate to participate in the study. * Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used in conjunction with the study or contrast sensitivity that can't be adequately pre-treated prior to the ablation procedure. * Positive pregnancy test results for female subjects of childbearing or potential or breast feeding. * Enrolment in a concurrent clinical study that in the judgement of the investigator would increase risk to the subject or deem the subject inappropriate to participate in the study. * Significant GI bleed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular tachycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Coventry and Warwickshire NHS Trust

    Coventry, West Midlands, CV22DX, United Kingdom

  • University Hospitals Sussex NHS Foundation Trust

    Brighton, BN2 1ES, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.